文献速递骨质疏松与钙磷/甲状旁腺

CYP24A1突变杂合携带者生化表型与野生型的差异

Do the Heterozygous Carriers of a CYP24A1 Mutation Display a Different Biochemical Phenotype Than Wild Types?
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

本研究在一个携带CYP24A1无义致病性变异p.Arg223*的大家系中,比较杂合携带者与野生型对照的临床和生化特征。结果显示杂合子血清钙和25(OH)D3浓度显著高于野生型,但其他生化指标及肾结石发生率无差异,提示杂合子具有不同生化表型,临床需关注其潜在高钙血症风险。

要点

  • CYP24A1杂合携带者血清钙和25(OH)D3水平高于野生型。
  • 杂合子与野生型在肾结石发生率及其他生化指标上无差异。
  • 杂合子若暴露于触发因素,可能需监测高钙血症风险。

核心结论

  • CYP24A1杂合携带者表现出与野生型不同的生化表型,血清钙和25(OH)D3更高。

研究设计与样本

  • 对一个携带CYP24A1无义致病性变异p.Arg223*的大家系进行临床和生化评估,并按基因型分为杂合子与野生型两组。

主要发现

  • 先证者为40岁男性纯合子,有轻度高钙血症伴季节波动、复发性肾结石,无急性高钙血症发作。
  • 先证者血清FGF23最高、25(OH)D3/24,25(OH)2D3比值最高且1,24,25(OH)3D3检测不到。

关键数值与推荐

  • 先证者1,24,25(OH)3D3检测不到,25(OH)D3/24,25(OH)2D3比值最高。

临床怎么用

  • 临床实践中,CYP24A1杂合携带者可能需监测,因暴露于触发因素时有发生高钙血症及相关临床表现的潜在风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Human cytochrome P450 24 subfamily A member 1 (CYP24A1) loss-of-function mutations result in impaired activity of the 24-hydroxylase involved in vitamin D catabolism, thus inducing a vitamin D-dependent hypercalcemia. Homozygotes often present an overt clinical phenotype named idiopathic infantile hypercalcemia (IIH), whereas it is debated whether heterozygotes display an abnormal phenotype. OBJECTIVE: To compare the clinical and biochemical features of heterozygous carriers of CYP24A1 variant and healthy wild-type controls sharing the same genetic and environmental exposure. METHODS: A large family harboring the nonsense c.667A>T, p.Arg223* pathogenic variant in the CYP24A1 gene was evaluated. All subjects underwent clinical and biochemical evaluation and complete analysis of vitamin D metabolites using mass spectroscopy including 1,24,25(OH)3D3. Subjects were divided into 2 groups according to their genotype: heterozygotes and wild-type for the CYP24A1 variant. RESULTS: The proband, a 40-year-old man, homozygous for p.Arg223* pathogenic variant, had a history of mild hypercalcemia with a seasonal trend, recurrent nephrolithiasis, and no episodes of acute hypercalcemia. He showed the highest serum levels of fibroblast growth factor 23, the highest 25(OH)D3/24,25(OH)2D3 ratio and undetectable levels of 1,24,25(OH)3D3, which represent indicators of a loss-of-function CYP24A1. Compared with the wild-types, heterozygotes had higher serum calcium and 25(OH)D3 concentrations (P = .017 and P = .025, respectively), without any difference in the other biochemical parameters and in the rate of nephrolithiasis. CONCLUSION: Heterozygotes exhibit a biochemical phenotype different from that of wild-type subjects. In clinical practice, these individuals might require surveillance because of the potential risk of developing hypercalcemia and related clinical manifestations if exposed to triggering factors.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Brancatella A, Cappellani D, Kaufmann M, et al. Do the Heterozygous Carriers of a CYP24A1 Mutation Display a Different Biochemical Phenotype Than Wild Types? J Clin Endocrinol Metab. 2021. PMID: 33249478. doi:10.1210/clinem/dgaa876

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。